Physician profile
Ryan S Evans
NPI 1346508793
$15,655.37
in general payments reported to CMS, 2019-2025
43 companies · $2,665 in 2025
The $2,665 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,263 · 2020: $764 · 2021: $1,667 · 2022: $2,385 · 2023: $2,501 · 2024: $2,410 · 2025: $2,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,401 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,400.82 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,853.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,460.61 | 2019-2025 | |
| Pfizer INC. | $1,310.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,294.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,231.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,039.15 | 2019-2025 | Otezla, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $966.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $897.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $849.56 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $555.89 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $463.65 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.59 | 2019-2025 | Synjardy, Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $391.37 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $350.90 | 2021-2025 | |
| Amarin Pharma, INC. | $321.87 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.